Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc. (OBIO): 4 pipeline candidates · ~12 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
12.4 months
7% dilution
Lead: Phase 3
4 candidates
N/A
6 buys · 2 sells (180d)
A transparent, data-derived signal for Orchestra BioMed Holdings Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$230.5M
Cash
$28.4M
Quarterly Burn
$22.2M
Runway
12.4 mo
Revenue
$110K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| avim therapy | Phase 3 |
| backbeat cnt | Phase 3 |
| cnt-hf | Preclinical |
| virtue sab | Phase 3 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
64
Total value held
$125.0M
| Holder | Shares | Value |
|---|---|---|
| perceptive advisors llc | 10,075,812 | $42.8M |
| rtw investments, lp | 8,306,063 | $35.3M |
| vanguard capital management llc | 4,408,638 | $18.7M |
| alyeska investment group, l.p. | 1,000,000 | $4.3M |
| millennium management llc | 702,543 | $3.0M |
| blackrock, inc. | 635,714 | $2.7M |
| geode capital management, llc | 485,492 | $2.1M |
| affinity asset advisors, llc | 402,550 | $1.7M |
| charles schwab investment management inc | 265,499 | $1.1M |
| knott david m jr | 253,651 | $1.1M |
Showing top 10 of 64 institutional holders of Orchestra BioMed Holdings Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Orchestra BioMed Holdings Inc.'s pipeline?
Orchestra BioMed Holdings Inc. (OBIO) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Orchestra BioMed Holdings Inc.'s lead drug candidate?
Orchestra BioMed Holdings Inc.'s most advanced tracked candidate is avim therapy (Phase 3) for Hypertension in patients indicated for a cardiac pacemaker.
What is Orchestra BioMed Holdings Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Orchestra BioMed Holdings Inc. has approximately 12.4 months of cash runway.
What is Orchestra BioMed Holdings Inc.'s market capitalization?
Orchestra BioMed Holdings Inc.'s market capitalization is approximately $230.5M.
Who is the CEO of Orchestra BioMed Holdings Inc.?
Mr. David P. Hochman is the chief executive officer of Orchestra BioMed Holdings Inc. (OBIO).
Get the full picture on Orchestra BioMed Holdings Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.